The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial.
Acute Coronary Syndrome
/ therapy
Aged
Aspirin
/ administration & dosage
Body Mass Index
Coronary Artery Disease
/ therapy
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Myocardial Infarction
/ epidemiology
Percutaneous Coronary Intervention
/ methods
Platelet Aggregation Inhibitors
/ administration & dosage
Prospective Studies
Ticagrelor
/ administration & dosage
Time Factors
Treatment Outcome
Acute coronary syndrome
Body mass index
Drug-eluting stent
Dual antiplatelet therapy
Percutaneous coronary intervention
Ticagrelor monotherapy
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
03
12
2019
accepted:
16
01
2020
pubmed:
2
2
2020
medline:
17
7
2021
entrez:
2
2
2020
Statut:
ppublish
Résumé
The efficacy of antiplatelet therapies following percutaneous coronary intervention (PCI) may be affected by body mass index (BMI). This is a prespecified subgroup analysis of the GLOBAL LEADERS trial, a prospective, multicenter, open-label, randomized controlled trial in an all-comer population undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with a reference regimen (12-month aspirin monotherapy following 12-month DAPT). A total of 15,968 patients were stratified by baseline BMI with prespecified threshold of 27 kg/m Overall, BMI did not influence the treatment effect seen with ticagrelor monotherapy; however, a beneficial effect of ticagrelor monotherapy was seen in ACS patients with BMI < 27 kg/m The trial has been registered with ClinicalTrials.gov, Number NCT01813435.
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of antiplatelet therapies following percutaneous coronary intervention (PCI) may be affected by body mass index (BMI).
METHODS AND RESULTS
RESULTS
This is a prespecified subgroup analysis of the GLOBAL LEADERS trial, a prospective, multicenter, open-label, randomized controlled trial in an all-comer population undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with a reference regimen (12-month aspirin monotherapy following 12-month DAPT). A total of 15,968 patients were stratified by baseline BMI with prespecified threshold of 27 kg/m
CONCLUSIONS
CONCLUSIONS
Overall, BMI did not influence the treatment effect seen with ticagrelor monotherapy; however, a beneficial effect of ticagrelor monotherapy was seen in ACS patients with BMI < 27 kg/m
TRIAL REGISTRATION
BACKGROUND
The trial has been registered with ClinicalTrials.gov, Number NCT01813435.
Identifiants
pubmed: 32006156
doi: 10.1007/s00392-020-01604-1
pii: 10.1007/s00392-020-01604-1
pmc: PMC7449952
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Ticagrelor
GLH0314RVC
Aspirin
R16CO5Y76E
Banques de données
ClinicalTrials.gov
['NCT01813435']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1125-1139Références
EuroIntervention. 2016 Nov 20;12(10):1239-1245
pubmed: 26606735
Eur Heart J. 2016 Nov 21;37(44):3347-3356
pubmed: 26516174
JAMA Cardiol. 2019 Nov 1;4(11):1092-1101
pubmed: 31557763
Obes Rev. 2012 Jan;13(1):27-42
pubmed: 21917110
Heart. 2010 Nov;96(21):1693-4
pubmed: 20956485
J Am Coll Cardiol. 2019 Nov 5;74(18):2223-2234
pubmed: 31672177
J Am Coll Cardiol. 2019 Oct 22;74(16):2015-2027
pubmed: 31623758
J Am Coll Cardiol. 2002 Mar 6;39(5):834-40
pubmed: 11869849
J Thromb Haemost. 2018 Apr;16(4):663-669
pubmed: 29443445
JACC Cardiovasc Interv. 2018 Jan 8;11(1):68-76
pubmed: 29248412
Am J Cardiol. 2007 Jul 15;100(2):203-5
pubmed: 17631070
Nat Rev Drug Discov. 2006 Jan;5(1):75-86
pubmed: 16485347
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
Circ Res. 2005 May 13;96(9):939-49
pubmed: 15890981
Br J Clin Pharmacol. 2019 Feb;85(2):413-421
pubmed: 30414387
J Am Coll Cardiol. 2015 Dec 15;66(23):2648-2662
pubmed: 26670066
JACC Cardiovasc Interv. 2017 Jul 10;10(13):1283-1292
pubmed: 28683933
Am J Cardiol. 2019 Dec 15;124(12):1833-1840
pubmed: 31648781
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Br J Haematol. 2000 Sep;110(4):925-34
pubmed: 11054084
Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):183-191
pubmed: 28838094
Eur Heart J. 2018 Apr 1;39(13):1078-1085
pubmed: 29390064
J Am Coll Cardiol. 2010 Feb 23;55(8):815-22
pubmed: 20170822
Am J Cardiol. 2013 Apr 15;111(8):1131-8
pubmed: 23375187
Lancet. 2006 Aug 19;368(9536):666-78
pubmed: 16920472
Eur Heart J. 2019 Sep 14;40(35):2937-2938
pubmed: 31520584
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
J Am Coll Cardiol. 2002 Feb 20;39(4):578-84
pubmed: 11849854
Am J Cardiol. 2010 Feb 15;105(4):475-9
pubmed: 20152241
JAMA. 2015 Aug 18;314(7):687-99
pubmed: 26284720
Circulation. 2018 Jun 21;:
pubmed: 29930021
Clin Res Cardiol. 2020 Jul;109(7):918-929
pubmed: 31828504
Lancet. 2018 Sep 15;392(10151):940-949
pubmed: 30166073
N Engl J Med. 2008 Nov 13;359(20):2105-20
pubmed: 19005195
J Cardiovasc Transl Res. 2014 Feb;7(1):19-28
pubmed: 24309957
JACC Cardiovasc Interv. 2017 Dec 26;10(24):2560-2570
pubmed: 29268886
Thromb Res. 2015 Oct;136(4):712-6
pubmed: 26205154
Clin Res Cardiol. 2019 Nov;108(11):1215-1225
pubmed: 30953180
JACC Cardiovasc Interv. 2013 Aug;6(8):854-63
pubmed: 23968703
Circulation. 2018 Feb 27;137(9):961-972
pubmed: 29483172
Eur Heart J. 2019 Aug 14;40(31):2595-2604
pubmed: 31397487
J Thromb Haemost. 2011 Mar;9(3):552-61
pubmed: 21143373
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
JACC Cardiovasc Interv. 2013 Sep;6(9):897-904
pubmed: 24050858
Am J Cardiol. 2009 Feb 2;103(3 Suppl):27A-34A
pubmed: 19166710